Navigation Links
Depomed Announces Appointment of Srinivas G. Rao, MD, PhD, as Chief Medical Officer
Date:7/16/2014

NEWARK, Calif., July 16, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced the appointment of Srinivas G. Rao, MD, PhD, as Chief Medical Officer and Senior Vice President.   Dr. Rao has extensive experience and background in pain and central nervous system diseases. He was the Founder and Chief Executive Officer of Kyalin Biosciences, a privately held biotechnology company developing a potential breakthrough therapy for autism, from its formation in 2011 through to its sale to Retrophin, Inc in 2013.  In 2014, he served as Executive Vice President and Head of Neuroscience at Retrophin.  From 2011 to 2013, Dr. Rao also served as CMO and CSO of 3 companies through his association with Avalon Ventures.  Finally, from 2001 to 2011, he was Chief Scientific Officer of Cypress Bioscience where he had a broad range of responsibilities, from business to clinical development.  He was the innovator behind Savella™, postulating that this drug's unique pharmacology would be effective for fibromyalgia.   Savella™ was approved by the FDA for this indication in 2009. 

Dr. Rao received his MD from Yale School of Medicine and his PhD in neurobiology from Yale Graduate School.  Dr. Rao is a member of the American College of Neuropharmacology, the American Pain Society, International Association for the Study of Pain and the Society for Neuroscience. 

"We are delighted to have Srini join us as Chief Medical Officer", said Jim Schoeneck, President and Chief Executive Officer.  "His deep expertise in the areas of pain and neurology and his experience in in-licensing and directing the clinical development and approval of medicines to treat important CNS conditions make him a great fit for Depomed as we seek to expand our franchise in pain and central nervous system diseases."

"I am extremely pleased to be joining Depomed at this exciting time in the company's history," said Dr. Rao.  "I believe that Jim and the team at Depomed have accomplished a tremendous amount in the past few years and continue to move towards a leadership position in the field of pain and CNS related products.  I look forward to helping the company achieve that goal."

About Depomed

Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.  Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults.  Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology.   Additional information about Depomed may be found at www.depomed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995.  The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to the company's ability to acquire or in-license new products and the risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K for the year ended December 31, 2013 and the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.  The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans or objectives will be achieved.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

INVESTOR CONTACT:
August J. Moretti
Depomed, Inc.
510-744-8000
amoretti@depomed.com

MEDIA CONTACT:
Carolyn Hawley
Canale Communications for Depomed
619-849-5375
carolyn@canalecomm.com


'/>"/>
SOURCE Depomed, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Depomed To Present At Piper Jaffray 2013 Healthcare Conference
2. Depomed Reports Third Quarter 2013 Financial Results
3. Depomed To Report Third Quarter Fiscal Year 2013 Financial Results On Tuesday, November 5, 2013
4. Depomed Sells Type 2 Diabetes Royalties And Milestones To PDL BioPharma For $240.5 Million
5. PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed
6. Depomed Expands Geographic Scope of License Agreement with Merck for Extended Release Metformin Patents
7. Depomed Reports Second Quarter 2013 Financial Results
8. Depomed To Report Second Quarter Fiscal Year 2013 Financial Results On Wednesday, August 7, 2013
9. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
10. Depomed Announces Appointment of Louis J. Lavigne, Jr. to Board of Directors
11. Depomed to Present at Wells Fargo Securities 2013 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today ... December 31, 2015. The Company also filed its Quarterly Report ... 2016 with the Securities and Exchange Commission today. ... 2015 --> --> Net ... $2.6 million, or 95%, to $5.4 million from $2.8 million ...
(Date:2/11/2016)... , Feb. 11, 2016 Laboratory ... used in laboratories. These may range from microscope slides ... glassware is made from borosilicate glass because of its ... on the other hand, started gaining popularity over the ... easier to replace glass with plastic in several applications ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 12, 2016 , ... The Journal of ... from 0.416 in 2013. The SJR uses data taken from the Scopus database (Elsevier ... the number of citations received by the journal over a three year period and ...
(Date:2/11/2016)... ... 2016 , ... The president released a FY 2017 budget request on Tuesday ... of the cost burden to military beneficiaries. , MOAA’s president, retired Air Force ... as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We ...
(Date:2/11/2016)... ... 11, 2016 , ... Hall Integrative Health and Chiropractic, PC ... simultaneous grand openings in March. All seven practices are set to start accepting ... reversing diabetes possible? According to this 2011 CNN article it is possible: ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... women’s health, is pleased to announce the promotions of Allison Kelly to executive ... Steve Catone to executive vice president of North American capital sales, and Wendy ...
(Date:2/11/2016)... ... 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased ... Study for Plans and Purchasers.” Executives from Intel Corp. and Providence Health & ... health benefits program Connected Care, will discuss the challenges they faced (and how ...
Breaking Medicine News(10 mins):